Pages that link to "Q33443385"
Jump to navigation
Jump to search
The following pages link to De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and T (Q33443385):
Displaying 18 items.
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial (Q46419524) (← links)
- Trastuzumab emtansine: determining its role in management of HER2+ breast cancer (Q47795804) (← links)
- Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments (Q47851750) (← links)
- Optimal treatment of early stage HER2-positive breast cancer (Q57020377) (← links)
- Progress in adjuvant systemic therapy for breast cancer (Q57106079) (← links)
- Progress in targeted therapy for breast cancer (Q57109788) (← links)
- Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives (Q64107259) (← links)
- Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? (Q64325820) (← links)
- Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation. (Q64914318) (← links)
- Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profiles of HER2-Positive Breast Cancer Patients Enrolled for Neoadjuvant Targeted Chemotherapy (Q89511033) (← links)
- Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond (Q89727324) (← links)
- De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study (Q91693727) (← links)
- Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease (Q91989188) (← links)
- Systemic treatment of patients with early breast cancer: recent updates and state of the art (Q91989219) (← links)
- Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer (Q91989251) (← links)
- Adjuvant chemotherapy for node negative, high Recurrence ScoreTM breast cancer: in defense of de-escalation (Q92716353) (← links)
- A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer (Q92741938) (← links)
- Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis (Q93271903) (← links)